

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Oncologica

Supplementary materials

Table S1. Treatment of non-operated patients

Treatment of Non-Operated Patients	
Treatment	N = 79¹
Chemotherapy	10 / 79 (12.7%)
Chemoradiotherapy	13 / 79 (16.5%)
Radiotherapy	23 / 79 (29.1%)
Conventional RT	6 / 23 (26.1%)
SBRT	17 / 23 (73.9%)
Immuno-oncologic and targeted drugs	5 / 79 (6.3%)
BSC	28 / 79 (35.4%)

¹ n / N (%)

Table S2. 2- and 3-year OS rate of operated and non-operated patients according to stage

Overall Survival at 24 and 36 Months by Treatment Approach and Stage			
Variable	N	24 Month (95% CI)	36 Month (95% CI)
Operatively treated by stage	77		
I		88% (74, 94)	79% (65, 88)
II		65% (40, 82)	45% (23, 65)
III		67% (28, 88)	67% (28, 88)
Non-operatively treated by stage	79		
I		57% (37, 72)	53% (34, 69)
II		20% (4.9, 42)	6.7% (0.4, 26)
III		21% (9.1, 35)	15% (5.4, 28)

Figure S1. Overall survival of non-operated patients according to stage




Figure S2. Overall survival of non-operated patients according to treatment

